Key result
Teclistamab rapidly achieves complete response and restores heart transplant eligibility in advanced cardiac AL amyloidosis.
Why the study?
Does teclistamab induce hematologic response and restore heart transplant eligibility in a patient with advanced refractory AL cardiomyopathy?
Case Report (n=1)
Does teclistamab induce hematologic response and restore heart transplant eligibility in a patient with advanced refractory AL cardiomyopathy?
Teclistamab can serve as a fast-acting salvage therapy to achieve deep hematologic remission and restore heart transplant eligibility in patients with refractory AL cardiac amyloidosis.
Answers are grounded in this paper and cite their sources.
May bridge select patients with advanced cardiac AL amyloidosis to heart transplant; hypothesis-generating and warrants prospective confirmation before practice change.
BACKGROUND: Immunoglobulin light chain (AL) cardiac amyloidosis carries high mortality, particularly when refractory to standard plasma cell-directed therapy. Deep hematologic remission is essential for heart transplant eligibility. CASE SUMMARY: A 37-year-old woman with advanced AL cardiomyopathy and refractory plasma cell dyscrasia did not respond to daratumumab-based therapy and could not tolerate venetoclax. She developed rapidly progressive, inotrope-dependent heart failure. Salvage therapy with a B-cell maturation antigen-directed bispecific antibody, teclistamab, induced a rapid, minimal residual disease-negative complete hematologic response within 2 weeks. This enabled successful heart transplantation during the same hospitalization, with excellent early post-transplant outcomes and sustained remission. DISCUSSION: B-cell maturation antigen-directed bispecific antibodies can achieve rapid and profound hematologic responses in refractory AL amyloidosis, even in patients with advanced cardiac involvement, thereby restoring transplant eligibility. TAKE-HOME MESSAGE: Teclistamab achieved a rapid minimal residual disease-negative complete response within weeks, demonstrating its potential as a fast-acting salvage therapy capable of restoring heart transplant eligibility in advanced cardiac AL amyloidosis.
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2026) conducted a case report in Advanced Immunoglobulin Light Chain (AL) Amyloid Cardiomyopathy (n=1). Teclistamab was evaluated on Minimal residual disease-negative complete hematologic response. Teclistamab salvage therapy induced a minimal residual disease-negative complete hematologic response within 2 weeks, enabling successful heart transplantation in advanced AL cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: